Bridge Biotherapeutics (Korea) Probability of Future Stock Price Finishing Under 4120.0
| 288330 Stock | KRW 3,955 95.00 2.35% |
Bridge |
Bridge Biotherapeutics Target Price Odds to finish below 4120.0
The tendency of Bridge Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under W 4,120 after 90 days |
| 3,955 | 90 days | 4,120 | about 54.06 |
Based on a normal probability distribution, the odds of Bridge Biotherapeutics to stay under W 4,120 after 90 days from now is about 54.06 (This Bridge Biotherapeutics probability density function shows the probability of Bridge Stock to fall within a particular range of prices over 90 days) . Probability of Bridge Biotherapeutics price to stay between its current price of W 3,955 and W 4,120 at the end of the 90-day period is about 7.28 .
Assuming the 90 days trading horizon Bridge Biotherapeutics has a beta of -1.42. This suggests as returns on its benchmark rise, returns on holding Bridge Biotherapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Bridge Biotherapeutics is expected to outperform its benchmark. Additionally Bridge Biotherapeutics has an alpha of 0.338, implying that it can generate a 0.34 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Bridge Biotherapeutics Price Density |
| Price |
Predictive Modules for Bridge Biotherapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Bridge Biotherapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Bridge Biotherapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Bridge Biotherapeutics is not an exception. The market had few large corrections towards the Bridge Biotherapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Bridge Biotherapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Bridge Biotherapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.34 | |
β | Beta against Dow Jones | -1.42 | |
σ | Overall volatility | 903.34 | |
Ir | Information ratio | 0.03 |
Bridge Biotherapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Bridge Biotherapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Bridge Biotherapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Bridge Biotherapeutics had very high historical volatility over the last 90 days | |
| The company reported the revenue of 1.92 B. Net Loss for the year was (26.28 B) with loss before overhead, payroll, taxes, and interest of (1.12 B). | |
| Bridge Biotherapeutics has accumulated about 8.2 B in cash with (21.13 B) of positive cash flow from operations. | |
| Roughly 30.0% of the company shares are owned by insiders or employees |
Bridge Biotherapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Bridge Stock often depends not only on the future outlook of the current and potential Bridge Biotherapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Bridge Biotherapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 19.7 M | |
| Cash And Short Term Investments | 43.1 B |
Bridge Biotherapeutics Technical Analysis
Bridge Biotherapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Bridge Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Bridge Biotherapeutics. In general, you should focus on analyzing Bridge Stock price patterns and their correlations with different microeconomic environments and drivers.
Bridge Biotherapeutics Predictive Forecast Models
Bridge Biotherapeutics' time-series forecasting models is one of many Bridge Biotherapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Bridge Biotherapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Bridge Biotherapeutics
Checking the ongoing alerts about Bridge Biotherapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Bridge Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Bridge Biotherapeutics had very high historical volatility over the last 90 days | |
| The company reported the revenue of 1.92 B. Net Loss for the year was (26.28 B) with loss before overhead, payroll, taxes, and interest of (1.12 B). | |
| Bridge Biotherapeutics has accumulated about 8.2 B in cash with (21.13 B) of positive cash flow from operations. | |
| Roughly 30.0% of the company shares are owned by insiders or employees |
Other Information on Investing in Bridge Stock
Bridge Biotherapeutics financial ratios help investors to determine whether Bridge Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bridge with respect to the benefits of owning Bridge Biotherapeutics security.